| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the National Hospital for Nervous Diseases, Queen Square, London, England. Accepted for publication June 10, 1980.
Four patients with Eaton-Lambert syndrome, four patients with congenital myasthenia, and one patient with myasthenia gravis were treated with oral 4-aminopyridine for periods of up to 10 months, doses varying from 40 to 200 mg per day. Clinical and electrophysiologic assessment confirmed the effectiveness of the drug when given alone or in conjunction with anticholinesterases. At therapeutically effective doses, central side effects were frequent and unpredictable. Three patients had a generalized fit and one patient developed a confusional state. Adverse side effects must severely limit the place of 4-aminopyridine in the treatment of patients with these conditions.
Address correspondence and reprint requests to Professor Newsom-Davis, National Hospital for Nervous Diseases, Queen Square, London, WC1, England.
Accepted for publication June 10, 1980.
This article has been cited by other articles:
|
|
 |
|
  A. D. Goodman, T. R. Brown, J. A. Cohen, L. B. Krupp, R. Schapiro, S. R. Schwid, R. Cohen, L. N. Marinucci, A. R. Blight, and For the Fampridine MS-F202 Study Group Dose comparison trial of sustained-release fampridine in multiple sclerosis Neurology, October 7, 2008; 71(15): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.D. Goodman, J.A. Cohen, A. Cross, T. Vollmer, M. Rizzo, R. Cohen, L. Marinucci, and A.R. Blight Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study Multiple Sclerosis, April 1, 2007; 13(3): 357 - 368. [Abstract] [PDF]
|
|
|
|
 |
|
 X. Q. Wang, A. Y. Xiao, A. Yang, L. LaRose, L. Wei, and S. P. Yu Block of Na+,K+-ATPase and Induction of Hybrid Death by 4-Aminopyridine in Cultured Cortical Neurons J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 502 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Hayes, M. A. Katz, J. G. Devane, J. T. C. Hsieh, D. L. Wolfe, P. J. Potter, and A. R. Blight Pharmacokinetics of an Immediate-Release Oral Formulation of Fampridine (4-Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury J. Clin. Pharmacol., April 1, 2003; 43(4): 379 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Velez, F. Shirazi, C. Goto, G. Shepherd, and B. A. Roth Opisthotonic Posturing With Neuromuscular Irritability Attributable to 4-Aminopyridine Ingestion by a Healthy Pediatric Patient Pediatrics, January 1, 2003; 111(1): e82 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-Y. Tsao, J. R. Mendell, M. L. Friemer, and J. T. Kissel Lambert-Eaton Myasthenic Syndrome in Children J Child Neurol, January 1, 2002; 17(1): 74 - 76. [Abstract] [PDF]
|
|
|
|
 |
|
 K. J. Smith, P. A. Felts, and G. R. John Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension Brain, January 1, 2000; 123(1): 171 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Maddison, J. Newsom-Davis, and K. R Mills Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome J. Neurol. Neurosurg. Psychiatry, August 1, 1998; 65(2): 213 - 217. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Van Lunteren and M. Moyer Effects of DAP on diaphragm force and fatigue, including fatigue due to neurotransmission failure J Appl Physiol, November 1, 1996; 81(5): 2214 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Hughes and M. B. Katirji The Eaton-Lambert (Myasthenic) Syndrome in Association With Systemic Lupus Erythematosus Arch Neurol, November 1, 1986; 43(11): 1186 - 1187. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
